In the last trading session, 1.11 million shares of the Terns Pharmaceuticals Inc (NASDAQ:TERN) were traded, and its beta was -0.03. Most recently the company’s share price was $2.31, and it changed around $0.17 or 7.94% from the last close, which brings the market valuation of the company to $201.66M. TERN currently trades at a discount to its 52-week high of $11.40, offering almost -393.51% off that amount. The share price’s 52-week low was $1.87, which indicates that the current value has risen by an impressive 19.05% since then. We note from Terns Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.64 million shares, with the 3-month average coming to 1.40 million.
Terns Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.57. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended TERN as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Terns Pharmaceuticals Inc is expected to report earnings per share of -0.27 for the current quarter.
Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information
Instantly TERN has showed a green trend with a performance of 7.94% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.43 on recent trading dayincreased the stock’s daily price by 4.94%. The company’s shares are currently down -58.30% year-to-date, but still up 15.50% over the last five days. On the other hand, Terns Pharmaceuticals Inc (NASDAQ:TERN) is -27.36% down in the 30-day period. We can see from the shorts that 5.77 million shares have been sold at a short interest cover period of 5.95 day(s).
The consensus price target as assigned by Wall Street analysts is $20, which translates to bulls needing to increase their stock price by 88.45% from its current value. Analyst projections state that TERN is forecast to be at a low of $20 and a high of $20.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 16.38%. Terns Pharmaceuticals Inc earnings are expected to increase by -10.44% in 2025, but the outlook is negative -12.26% per year for the next five years.
TERN Dividends
Terns Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Mar-19.
Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.24% of Terns Pharmaceuticals Inc shares, and 102.13% of them are in the hands of institutional investors. The stock currently has a share float of 102.38%. Terns Pharmaceuticals Inc stock is held by 211.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 10.2326% of the shares, which is about 7.62 million shares worth $51.89 million.
VIVO CAPITAL, LLC, with 8.3038% or 6.18 million shares worth $42.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.07 shares worth $4.79 million, making up 2.37% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 1.83 shares worth around $4.22 million, which represents about 2.09% of the total shares outstanding.
